Radiation dosimetry and biodistribution of the hypoxia tracer 18F-EF5 in oncologic patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 7, 2012, Pages 412-419

  Lin, Lilie L ^a   Silvoniemi, Antti ^b   Stubbs, James B ^c   Rengan, Ramesh ^a   Suilamo, Sami ^b   Solin, Olof ^b   Divgi, Chaitanya ^d   Eskola, Olli ^b   Sorger, Jonathan M ^e   Stabin, Michael G ^f   Kachur, Alexander ^a   Hahn, Stephen M ^a   Grönroos, Tove J ^b   Forsback, Sarita ^b   Evans, Sydney M ^a   Koch, Cameron J ^a   Minn, Heikki ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c Radiation Dosimetry Systems   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VARIAN MEDICAL SYSTEMS   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

18F EF5; EF5; hypoxia; molecular imaging; PET

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLADDER; BLADDER WALL; BLOOD SAMPLING; BODY TEMPERATURE; BREATHING RATE; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ECG ABNORMALITY; FEMALE; HEART RATE; HUMAN; HYPOXIA; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION EXPOSURE; RADIOISOTOPE DISTRIBUTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

ADULT; CELL HYPOXIA; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETANIDAZOLE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; URINARY BLADDER; YOUNG ADULT;

EID: 84866271833     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1130     Document Type: Article

References (22)

1. Wilson WR, Hay MP. Targeting Hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393.
2. Hockel M, Knoop C, Schlenger K, et al. Intratumor pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45.
3. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31.
4. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285.
5. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with nodenegative cervix cancer. J Clin Oncol 2002;20:680.
6. Koh W-J, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Biol Oncol Phys 1992;22:199.
7. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233.
8. Koch CJ, Hahn SM, Rockwell KJ, et al. Pharmacokinetics of the 2-nitroimidazole EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl)acetamide] in human patients: Implications for hypoxia measurements in vivo. Cancer Chemother Pharmacol 2001;48:177.
9. Koch CJ. Measurement of Absolute Oxygen Levels in Cells and Tissues using Oxygen Sensors and 2-nitroimidazole EF5. Methods Enzymol 2002;352:3-31. (Pubitemid 41103167)
10. Kumar P, Stypinski D, Xia H, et al. Fluoroazomycin arabinoside (FAZA): Synthesis, 2H and 3H-labelling and preliminary biological evaluation of a novel 2-nitromidazole marker of tissue hypoxia. J Label Comp Radiopharm 1999;42:3.
11. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886.
12. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177.
13. Varghese AJ, Whitmore GF. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res 1980;40:2165.
14. Raleigh JA, Koch CJ. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol 1990;40:2457.
15. Koch CJ, Scheuermann JS, Divgi C, et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nuc Med Mol Imaging 2010; 37:2048.
16. Dolbier WR, Li A-R, Koch CJ et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001;54:73.
17. Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997;24: 677.
18. Surti S, Karp JS. Imaging characteristics of a 3-dimensional GSO whole-body PET camera. J Nucl Med 2004;45:1040.
19. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46: 1023.
20. Komar G, Seppänen M, Eskola O, et al. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944.
21. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1988;18:1.
22. Graham MM, Peterson LM, Link JM, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997;38:1631.